Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

9.190
-0.330-3.47%
Volume:135.37M
Turnover:1.24B
Market Cap:105.89B
PE:27.05
High:9.510
Open:9.510
Low:9.015
Close:9.520
52wk High:11.203
52wk Low:6.387
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:1.02
T/O Rate:1.17%
Dividend:0.30
Dividend Rate:3.31%
EPS(LYR):0.340
ROE:20.90%
ROA:10.70%
PB:2.41
PE(LYR):27.05
PS:2.90

Loading ...

CSPC Pharma's CRB-701 (SYS 6002) Gets FDA Nod for Phase 2 Trial in Oropharyngeal Cancer

Stock News
·
Jul 29

CSPC Says FDA Clears Crb-701 Pivotal Trial in Second-line Oropharyngeal Cancer

Reuters
·
Jul 29

CSPC Pharmaceutical - Crb-701 Receives FDA Clearance for Registrational Trial in Second-Line Oropharyngeal Cancer

THOMSON REUTERS
·
Jul 29

CSPC Pharmaceutical Group Stock Rallies 3.2% in Hong Kong, Outperforms Competitors

Dow Jones
·
Jul 29

Movement Alert|CSPC PHARMA Rises 3.06% in Regular Trading, Mid-Term Profit Alert and Multiple Pipeline Catalysts Continue to Ferment

Market Focus
·
Jul 29

Citi Reaffirms Buy Rating on CSPC Pharma, Sets Price Target at HK$11.50

Deep News
·
Jul 29

Citi: CSPC Pharma's (01093) Interim Profit Alert Far Exceeds Expectations, 'Buy' Rating Reaffirmed

Stock News
·
Jul 28

China's CSPC Pharmaceutical Rises on Robust H1 Earnings Forecast

Reuters
·
Jul 28

CSPC Pharma's Depression Drug Meets Primary Endpoint in Phase 3 Trial

MT Newswires Live
·
Jul 28

CSPC Pharma's Sirolimus Drug Application Accepted in China

MT Newswires Live
·
Jul 28

Movement Alert|CSPC PHARMA Rises 3.86% in Regular Trading, Interim Profit Forecast Surges as Antidepressant Drug Phase III Trial Hits Primary Endpoint

Market Focus
·
Jul 28

Hong Kong Stock Market Preview: Disease Prevention 15th Five-Year Plan Issued, SK Hynix Breaches IPO Price on Wall Street

Stock News
·
Jul 28

Cspc Pharmaceutical Says Phase III Trial of Ha1406 Meets Primary Endpoint

Reuters
·
Jul 27

CSPC PHARMA's Injectable Sirolimus (Albumin-Bound) New Drug Application Accepted by China's NMPA

Stock News
·
Jul 27

CSPC Pharma: Ammoxetine (HA1406) Clears Phase III with Statistically Significant Efficacy in Depression

Bulletin Express
·
Jul 27

CSPC Says China NMPA Accepts Sirolimus Albumin-bound Injection Filing, Grants Priority Review

Reuters
·
Jul 27

CSPC Pharmaceutical - Nmpa Accepts New Drug Application for Sirolimus for Injection (Albumin-Bound)

THOMSON REUTERS
·
Jul 27

CSPC Pharmaceutical - Phase Iii Trial of Ha1406 for Depression Meets Primary Endpoint with Statistical Significance

THOMSON REUTERS
·
Jul 27

CSPC PHARMA (01093) Issues Positive Profit Alert, Expects Significant Interim Net Profit Growth to Around RMB 5.9-6.2 Billion

Stock News
·
Jul 27

CSPC Innovation Pharma, CSPC Pharmaceutical Group Unit, Forecasts H1 Net Profit at 1.18 Billion-1.36 Billion Yuan

Reuters
·
Jul 27